These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 26022817)

  • 1. Intestinal cholesterol absorption, treatment with atorvastatin, and cardiovascular risk in hemodialysis patients.
    Silbernagel G; Fauler G; Genser B; Drechsler C; Krane V; Scharnagl H; Grammer TB; Baumgartner I; Ritz E; Wanner C; März W
    J Am Coll Cardiol; 2015 Jun; 65(21):2291-8. PubMed ID: 26022817
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effective prevention of cardiovascular disease and diabetes-related events with atorvastatin in Japanese elderly patients with type 2 diabetes mellitus: adjusting for treatment changes using a marginal structural proportional hazards model and a rank-preserving structural failure time model.
    Shinozaki T; Matsuyama Y; Iimuro S; Umegaki H; Sakurai T; Araki A; Ohashi Y; Ito H;
    Geriatr Gerontol Int; 2012 Apr; 12 Suppl 1():88-102. PubMed ID: 22435944
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Atorvastatin and low-density lipoprotein cholesterol in type 2 diabetes mellitus patients on hemodialysis.
    März W; Genser B; Drechsler C; Krane V; Grammer TB; Ritz E; Stojakovic T; Scharnagl H; Winkler K; Holme I; Holdaas H; Wanner C;
    Clin J Am Soc Nephrol; 2011 Jun; 6(6):1316-25. PubMed ID: 21493741
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis.
    Wanner C; Krane V; März W; Olschewski M; Mann JF; Ruf G; Ritz E;
    N Engl J Med; 2005 Jul; 353(3):238-48. PubMed ID: 16034009
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High cholesterol absorption is associated with increased cardiovascular risk in haemodialysis patients: insights from the AURORA study.
    Silbernagel G; Duarte K; Sadiku S; Fauler G; März W; Schmieder RE; Jardine AG; Massy ZA; Girerd N; Fellström B; Rossignol P; Scharnagl H; Zannad F
    Eur J Prev Cardiol; 2022 Oct; 29(13):1731-1739. PubMed ID: 35512252
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cholesterol metabolism and statin effectiveness in hemodialysis patients.
    Baigent C
    J Am Coll Cardiol; 2015 Jun; 65(21):2299-301. PubMed ID: 26022818
    [No Abstract]   [Full Text] [Related]  

  • 7. Low-dose atorvastatin in severe chronic kidney disease patients: a randomized, controlled endpoint study.
    Stegmayr BG; Brännström M; Bucht S; Crougneau V; Dimeny E; Ekspong A; Eriksson M; Granroth B; Gröntoft KC; Hadimeri H; Holmberg B; Ingman B; Isaksson B; Johansson G; Lindberger K; Lundberg L; Mikaelsson L; Olausson E; Persson B; Stenlund H; Wikdahl AM;
    Scand J Urol Nephrol; 2005; 39(6):489-97. PubMed ID: 18161210
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduction in cardiovascular events after vascular surgery with atorvastatin: a randomized trial.
    Durazzo AE; Machado FS; Ikeoka DT; De Bernoche C; Monachini MC; Puech-Leão P; Caramelli B
    J Vasc Surg; 2004 May; 39(5):967-75; discussion 975-6. PubMed ID: 15111846
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Focused atorvastatin therapy in managed-care patients with coronary heart disease and CKD.
    Koren MJ; Davidson MH; Wilson DJ; Fayyad RS; Zuckerman A; Reed DP;
    Am J Kidney Dis; 2009 May; 53(5):741-50. PubMed ID: 19216014
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study.
    Shepherd J; Kastelein JJ; Bittner V; Deedwania P; Breazna A; Dobson S; Wilson DJ; Zuckerman A; Wenger NK;
    J Am Coll Cardiol; 2008 Apr; 51(15):1448-54. PubMed ID: 18402899
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differences between statins on clinical endpoints: a population-based cohort study.
    Dieleman JP; van Wyk JT; van Wijk MA; van Herpen G; Straus SM; Dunselman H; Sturkenboom MC
    Curr Med Res Opin; 2005 Sep; 21(9):1461-8. PubMed ID: 16197665
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modeling the 4D Study: statins and cardiovascular outcomes in long-term hemodialysis patients with diabetes.
    Chan KE; Thadhani R; Lazarus JM; Hakim RM
    Clin J Am Soc Nephrol; 2010 May; 5(5):856-66. PubMed ID: 20338963
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum levels of lipoprotein(a) and homocysteine in patients on hemodialysis who take hydroxymethylglutaryl-CoA reductase inhibitors, vitamin B6, and folic acid.
    Shojaei MH; Djalali M; Siassi F; Khatami MR; Boroumand MA; Eshragian MR
    Iran J Kidney Dis; 2009 Jul; 3(3):141-4. PubMed ID: 19617662
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intensive lipid lowering with atorvastatin in patients with stable coronary disease.
    LaRosa JC; Grundy SM; Waters DD; Shear C; Barter P; Fruchart JC; Gotto AM; Greten H; Kastelein JJ; Shepherd J; Wenger NK;
    N Engl J Med; 2005 Apr; 352(14):1425-35. PubMed ID: 15755765
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lessons learnt from the 4D trial.
    Wanner C; Krane V
    Nephrol Ther; 2006 Feb; 2(1):3-7. PubMed ID: 16895709
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Markers of cholesterol absorption and synthesis predict the low-density lipoprotein cholesterol response to atorvastatin.
    Hoenig MR; Walker PJ; Gurnsey C; Beadle K; Johnson L
    J Cardiovasc Pharmacol; 2010 Oct; 56(4):396-401. PubMed ID: 20625310
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of Atorvastatin-induced very low-density lipoprotein cholesterol levels in Patients with coronary heart disease (a post hoc analysis of the treating to new targets [TNT] study).
    LaRosa JC; Grundy SM; Kastelein JJ; Kostis JB; Greten H;
    Am J Cardiol; 2007 Sep; 100(5):747-52. PubMed ID: 17719314
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS).
    Colhoun HM; Betteridge DJ; Durrington PN; Hitman GA; Neil HA; Livingstone SJ; Charlton-Menys V; DeMicco DA; Fuller JH;
    Am J Kidney Dis; 2009 Nov; 54(5):810-9. PubMed ID: 19540640
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiovascular outcomes among patients newly initiating atorvastatin or simvastatin therapy: a large database analysis of managed care plans in the United States.
    Foody JM; Joyce AT; Rudolph AE; Liu LZ; Benner JS
    Clin Ther; 2008 Jan; 30(1):195-205. PubMed ID: 18343257
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of atorvastatin and vitamin E on lipoproteins and oxidative stress in dialysis patients: a randomised-controlled trial.
    Diepeveen SH; Verhoeven GW; Van Der Palen J; Dikkeschei LD; Van Tits LJ; Kolsters G; Offerman JJ; Bilo HJ; Stalenhoef AF
    J Intern Med; 2005 May; 257(5):438-45. PubMed ID: 15836660
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.